Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan vs Norditropin in Japanese Adults with AGHD
NCT03075644Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2017
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of somapacitan in adult growth hormone deficiency (AGHD), sponsored by Novo Nordisk. Started Mar 2017; status: completed.
02
Drugs
somapacitan
03
Conditions
adult growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on NCT03075644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075644.